Fenwick & West represented BioAge Labs in the transaction. BioAge Labs (BioAge) announced it completed the oversubscribed $170M Series D financing round led by Sofinnova Investments...
BioAge’s $170 Million Series D Financing Round
Eyconis’ Formation and Launch
Fenwick & West represented Eychonis, Inc. in the transaction. Eyconis, Inc. announced their formation and $150 million capital raise. Eyconis was formed and launched by Ascendis...
Veracyte’s Acquisition of C2i Genomics
Fenwick & West is representing Veracyte in the transaction, and Meitar is representing C2i Genomics. Veracyte, Inc. (Nasdaq: VCYT) announced it has entered into a definitive agreement...
Recludix Pharma’s Collaboration with Sanofi
Fenwick & West represented Recludix Pharma in the deal. Recludix Pharma announced that it has entered into a strategic collaboration with Sanofi (NASDAQ: SNY) to develop and...
Eli Lilly’s $2.4 Billion Pending Acquisition of DICE THerapeutics
Fenwick & West LLP represented DICE Therapeutics, Inc. in the transaction, while Kirkland & Ellis represented Eli Lilly and Company. Eli Lilly and Company (NYSE: LLY)...
Novartis AG’s Acquisition of Chinook Therapeutics
Fenwick & West LLP represented Chinook Therapeutics, Inc. on the transaction, while Hogan Lovells US LLP represented Novartis AG. Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company, announced...
Belharra Therapeutics’ Multi-year Collaboration with Genentech
Fenwick represented Belharra Therapeutics on the deal. Belharra Therapeutics, a privately held drug discovery company with a novel photoaffinity-based, non-covalent chemoproteomics platform, announced its multi-year collaboration with...
Idera Pharmaceuticals’ Acquisition of Aceragen
Fenwick represented Aceragen on the deal, Morgan Lewis advised Idera Pharmaceuticals. Aceragen, a privately-held biotechnology company addressing rare, orphan pulmonary and rheumatic diseases for which there...
Scribe Therapeutics’ Collaboration with Sanofi
Fenwick represented Scribe Therapeutics on the deal. Scribe Therapeutics, a molecular engineering company pioneering a CRISPR by Design™ platform for genetic medicine, announced its strategic collaboration and...
Melinta Therapeutics’ Acquisition of U.S. Rights to TOPROL-XL from New American Therapeutics
Fenwick advised Melinta Therapeutics on the deal. Melinta Therapeutics, a company providing innovative therapies for acute and life-threatening illnesses, announced its acquisition of the U.S. rights to...
Snowflake’s Acquisition of Streamlit
Baker McKenzie advised Snowflake on the deal while Fenwick represented Streamlit. Snowflake executed the acquisition of Streamlit, a framework built to simplify and accelerate the creation of...
Metagenomi’s Collaboration with Moderna
Fenwick & West and Wilson Sonsini Goodrich & Rosati represented Metagenomi on the deal. Metagenomi, Inc., a genetic medicines company with a versatile portfolio of next-generation...